<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="186347">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00667875</url>
  </required_header>
  <id_info>
    <org_study_id>ANTON-1R21AA017525-01</org_study_id>
    <secondary_id>R21AA017525</secondary_id>
    <secondary_id>NIH Grant AA017525-01</secondary_id>
    <nct_id>NCT00667875</nct_id>
  </id_info>
  <brief_title>An Exploratory Study of Naltrexone Plus Aripiprazole for Alcohol Dependence</brief_title>
  <acronym>NALAPZ</acronym>
  <official_title>An Exploratory Study of Naltrexone Plus Aripiprazole for Alcohol Dependence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of South Carolina</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Alcohol Abuse and Alcoholism (NIAAA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Medical University of South Carolina</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The principal aim of this exploratory study is to examine whether the addition of
      aripiprazole to naltrexone will enhance efficacy over naltrexone alone in a 16-week
      randomized, placebo-controlled clinical trial, in which all subjects will be provided
      medical management as delivered in the COMBINE Study (Anton et al, 2006). To test whether
      medication treatment will reduce drinking compared to placebo treatment alone in the context
      of medical management and whether naltrexone plus aripiprazole will reduce drinking compared
      to naltrexone treatment alone in the context of medical management.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">May 2011</completion_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Drinks Per Drinking Day</measure>
    <time_frame>16-week treatment period</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pill Counts and Urinary Riboflavin Levels During Treatment</measure>
    <time_frame>16-week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject-reported Adverse Events on the SAFTEE Interview</measure>
    <time_frame>16-week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Heavy Drinking Days Over the 16-week Study</measure>
    <time_frame>16-weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Alcohol Dependence</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Naltrexone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Naltrexone + Aripiprazole</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naltrexone</intervention_name>
    <description>Naltrexone (25mg or 50 mg per titration schedule)</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naltrexone + Aripiprazole</intervention_name>
    <description>Naltrexone + Aripiprazole (5mg - 15mg per titration schedule)</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 18 70

          2. Subjects will meet criteria for primary alcohol dependence operationalized as
             follows:

             A. Meets the DSM IV criteria for alcohol dependence including loss of control over
             drinking (criterion 3) B. Has not had more than one previous inpatient medical
             detoxification

          3. Consumes, on average, at least 10 standard drinks per drinking day for men and 8
             drinks per day for women in the 90 days pre-screening (to select an appropriately
             heavy drinking population)

          4. Able to maintain sobriety for four days (with or without the aid of alcohol
             detoxification medications) as determined by self report, collateral report, and
             breathalyzer measurements

          5. Able to read and understand questionnaires and informed consent

          6. Lives within approximately 50 miles of the study site -

        Exclusion Criteria:

          1. Currently meets DSM IV criteria for any other psychoactive substance dependency
             disorder except nicotine dependence

          2. Ever abused opiates

          3. Any psychoactive substance abuse, except marijuana and nicotine, within the last 30
             days as evidenced by subject report, collateral report, or urine drug screen

          4. Meets DSM IV criteria for current axis I disorders of major depression, panic
             disorder, obsessive compulsive disorder, post traumatic stress syndrome, bipolar
             affective disorder, schizophrenia, or any other psychotic disorder or organic mental
             disorder

          5. Meets DSM IV current criteria for dissociative disorder or eating disorders

          6. Has current suicidal ideation or homicidal ideation

          7. Need for maintenance or acute treatment with any psychoactive medication including
             anti-seizure medications

          8. Current use of disulfiram

          9. Clinically significant medical problems such as cardiovascular, renal, GI, or
             endocrine problem that would impair participation or limit medication ingestion

         10. Hepatocellular disease indicated by elevations of SGPT (ALT) and SGOT (AST) of at
             least 3.0 times normal at screening and/or after 5 days abstinence

         11. Sexually active female of child-bearing potential who is pregnant (by urine HCG),
             nursing, or who is not using a reliable form of birth control

         12. Has current charges pending for a violent crime (not including DUI-related offenses)

         13. Does not have a stable living situation and a reliable source of collateral reporting

         14. Has taken an opiate antagonist drug in the last month

         15. Has taken aripiprazole in the last month or has experienced adverse effects from it
             at any time in the past
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Raymond F Anton, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of South Carolina</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical University of South Carolina, Center for Drug and Alcohol Programs</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <lastchanged_date>March 17, 2016</lastchanged_date>
  <firstreceived_date>April 24, 2008</firstreceived_date>
  <firstreceived_results_date>March 17, 2016</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of South Carolina</investigator_affiliation>
    <investigator_full_name>Raymond F. Anton</investigator_full_name>
    <investigator_title>Distringuished University Professor</investigator_title>
  </responsible_party>
  <keyword>Alcohol Dependence</keyword>
  <keyword>Alcoholism</keyword>
  <keyword>Naltrexone</keyword>
  <keyword>Aripiprazole</keyword>
  <keyword>Substance Abuse</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Alcoholism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ethanol</mesh_term>
    <mesh_term>Aripiprazole</mesh_term>
    <mesh_term>Naltrexone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were recruited from the community in response to advertising in local papers, and radio</recruitment_details>
      <pre_assignment_details>Subjects were to remain abstinent for 4 days prior to starting treatment with the randomly assigned study drug.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>1 Placebo</title>
          <description>Placebo : placebo</description>
        </group>
        <group group_id="P2">
          <title>2 Naltrexone</title>
          <description>Naltrexone
Naltrexone : Naltrexone (25mg or 50 mg per titration schedule)</description>
        </group>
        <group group_id="P3">
          <title>3 Naltrexone Plus Aripiprazole</title>
          <description>Naltrexone + Aripiprazole
Naltrexone + Aripiprazole : Naltrexone + Aripiprazole (5mg - 15mg per titration schedule)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="23">3 subjects had no data after randomization and were excluded from analysis</participants>
                <participants group_id="P2" count="21"/>
                <participants group_id="P3" count="21">2 subjects had no data following randomization and were excluded from the analysis.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13">Subjects who dropped out during treatment are considered completed if they provide end of study data</participants>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="13"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>1 Placebo</title>
          <description>Placebo : placebo</description>
        </group>
        <group group_id="B2">
          <title>2 Naltrexone</title>
          <description>Naltrexone
Naltrexone : Naltrexone (25mg or 50 mg per titration schedule)</description>
        </group>
        <group group_id="B3">
          <title>3 Naltrexone Plus Aripiprazole</title>
          <description>Naltrexone + Aripiprazole
Naltrexone + Aripiprazole : Naltrexone + Aripiprazole (5mg - 15mg per titration schedule)</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="23"/>
            <count group_id="B2" value="21"/>
            <count group_id="B3" value="21"/>
            <count group_id="B4" value="65"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47" spread="9.6"/>
                    <measurement group_id="B2" value="47.2" spread="11.3"/>
                    <measurement group_id="B3" value="48.4" spread="10.2"/>
                    <measurement group_id="B4" value="47.6" spread="10.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Drinks Per Drinking Day</title>
        <time_frame>16-week treatment period</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Inactive Placebo</title>
            <description>Inactive placebo naltrexone + inactive placebo Aripiprazole</description>
          </group>
          <group group_id="O2">
            <title>Naltrexone and Inactive Placebo Aripiprazole</title>
            <description>Naltrexone: Naltrexone (25mg or 50 mg per titration schedule)</description>
          </group>
          <group group_id="O3">
            <title>Naltrexone + Aripiprazole</title>
            <description>Naltrexone + Aripiprazole: Naltrexone + Aripiprazole (5mg - 15mg per titration schedule)</description>
          </group>
        </group_list>
        <measure>
          <title>Drinks Per Drinking Day</title>
          <units>drinks per drinking day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.2" spread="4.4"/>
                    <measurement group_id="O2" value="7.8" spread="8.6"/>
                    <measurement group_id="O3" value="5.3" spread="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pill Counts and Urinary Riboflavin Levels During Treatment</title>
        <time_frame>16-week</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subject-reported Adverse Events on the SAFTEE Interview</title>
        <time_frame>16-week</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Heavy Drinking Days Over the 16-week Study</title>
        <time_frame>16-weeks</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Inactive Placebo</title>
          <description>Inactive placebo naltrexone + inactive placebo Aripiprazole</description>
        </group>
        <group group_id="E2">
          <title>Naltrexone and Inactive Placebo Aripiprazole</title>
          <description>Naltrexone: Naltrexone (25mg or 50 mg per titration schedule)</description>
        </group>
        <group group_id="E3">
          <title>Naltrexone + Aripiprazole</title>
          <description>Naltrexone + Aripiprazole: Naltrexone + Aripiprazole (5mg - 15mg per titration schedule)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>cardiac arrythmias</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>nausea and/or vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>restlessness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>fatigue or tiredness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>blurred vision</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>erectile dysfunction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Raymond F. Anton, MD</name_or_title>
      <organization>Medical University of South Carolina</organization>
      <phone>843-792-1226</phone>
      <email>antonr@musc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
